Trials / Completed
CompletedNCT01066715
Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 421 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study hypothesis is that XOMA 052 improves glycemic control in subjects with Type 2 Diabetes. Study X052078 is designed to establish efficacious dose(s) for future studies based on improvement in HbA1c.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XOMA 052 | Sterile solution subcutaneously administered monthly for 6 months |
| DRUG | Placebo | Sterile solution subcutaneously administered monthly for 6 months |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-02-10
- Last updated
- 2011-10-04
Locations
67 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01066715. Inclusion in this directory is not an endorsement.